| Literature DB >> 22193543 |
S Donzelli1, G Fontemaggi, F Fazi, S Di Agostino, F Padula, F Biagioni, P Muti, S Strano, G Blandino.
Abstract
p53 mutations have profound effects on non-small-cell lung cancer (NSCLC) resistance to chemotherapeutic treatments. Mutant p53 proteins are usually expressed at high levels in tumors, where they exert oncogenic functions. Here we show that p53R175H, a hotspot p53 mutant, induces microRNA (miRNA)-128-2 expression. Mutant p53 binds to the putative promoter of miR128-2 host gene, ARPP21, determining a concomitant induction of ARPP21 mRNA and miR-128-2. miR-128-2 expression in lung cancer cells inhibits apoptosis and confers increased resistance to cisplatin, doxorubicin and 5-fluorouracyl treatments. At the molecular level, miR-128-2 post-transcriptionally targets E2F5 and leads to the abrogation of its repressive activity on p21(waf1) transcription. p21(waf1) protein localizes to the cytoplasmic compartment, where it exerts an anti-apoptotic effect by preventing pro-caspase-3 cleavage. This study emphasizes miRNA-128-2 role as a master regulator in NSCLC chemoresistance.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22193543 PMCID: PMC3354056 DOI: 10.1038/cdd.2011.190
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 15.828